Advertisement
Table 1 Clinicopathological characteristics of 90 HER2-negative metastatic breast cancer patients with detectable CTCs in the peripheral blood samples at baseline
| Characteristic | Number of patients (%) |
|---|---|
| Age (years) | |
| < 40 | 9 (10.0) |
| ≥ 40 to < 60 | 64 (71.1) |
| ≥ 60 | 17 (18.9) |
| Menstrual status | |
| Premenopausal | 31 (34.4) |
| Menopausal | 59 (65.6) |
| ER status | |
| Positive | 71 (78.9) |
| Negative | 19 (21.1) |
| PR status | |
| Positive | 66 (73.3) |
| Negative | 24 (26.7) |
| HR status | |
| Positive | 74 (82.2) |
| Negative | 16 (17.8) |
| Disease-free survival (months) | |
| ≤ 12 | 18 (20.0) |
| > 12 to ≤ 24 | 9 (10.0) |
| > 24 to ≤ 60 | 34 (37.8) |
| > 60 | 29 (32.2) |
| Number of metastases | |
| Single | 4 (4.4) |
| Multiple | 86 (95.6) |
| Position of metastatic site | |
| Non-visceral | 31 (34.4) |
| Visceral | 59 (65.6) |
| Previous endocrinotherapy (after confirmed tumor relapse) | |
| None | 71 (78.9) |
| First-line | 15 (16.7) |
| Second-line or more | 4 (4.4) |
